Breast Cancer Info Now on Internet

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 5 No 1
Volume 5
Issue 1

NEW YORK--Women seeking information about breast cancer can now turn to their computers. The National Alliance of Breast Cancer Organizations (NABCO) has established the first nonprofit organization breast cancer web site (http://www.nabco.org) to provide In-ternet users with up-to-date information about the latest research, current treatment options, support services, and links to other Internet sites.

NEW YORK--Women seeking information about breast cancer can nowturn to their computers. The National Alliance of Breast CancerOrganizations (NABCO) has established the first nonprofit organizationbreast cancer web site (http://www.nabco.org) to provide In-ternetusers with up-to-date information about the latest research, currenttreatment options, support services, and links to other Internetsites.

The NABCO web site, initially supported through an educationalgrant from Rhône-Poulenc Rorer Oncology, has 10 separateareas within its own Home Page and links to other breast health-relatedsites.

Some of the areas that users of NABCO's Home Page will be ableto access include What's New, updated weekly; NABCO's latest factsheets; articles from NABCO News; legislative action notices;NABCO's events calendar; nationwide support groups; surveys aboutcurrent issues; NABCO resources; e-mail to NABCO's informationspecialists who answer questions about breast cancer; and informationabout how to join NABCO.

NABCO's debut on the Internet is part of an overall effort toexpand the organization's information and education programs.For more information about NABCO services, call 800-719-9154.

Recent Videos
Breast oncologist Jade E. Jones, MD, says she tries to send patients with BRCA-mutant HR-positive TNBC to clinical trials that use PARP inhibitors.
Following progression on a CDK4/6 inhibitor, ascertaining the endocrine sensitivity of HR-positive/HER2-negative disease may inform sequential treatment.
T-DXd improved progression-free survival over standard chemotherapy among patients with HR-positive/triple-negative breast cancer in DESTINY-Breast04.
The use of chemotherapy trended towards improved recurrence-free intervals in older patients with high-risk tumors as determined via the MammaPrint assay.
Use of a pharmacist-directed resource appears to improve provider confidence and adverse effect monitoring for patients undergoing infusion therapy.
Reshma L. Mahtani, DO, describes how updates from the DESTINY-Breast09, ASCENT-04, and VERITAC-2 trials may shift practices in the breast cancer field.
Multidisciplinary care can help ensure that treatment planning does not deviate from established guidelines for inflammatory breast cancer management.
Related Content